An Open Label Phase I Study to Evaluate the Safety and Efficacy of OBP-301 With Pembrolizumab in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 13 Dec 2017
At a glance
- Drugs Pembrolizumab (Primary) ; Telomelysin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 13 Dec 2017 According to an Oncolys BioPharma media release, first patient has been enrolled.
- 25 Oct 2017 Last checked against ClinicalTrials.gov record.
- 13 Oct 2017 Status changed from not yet recruiting to recruiting.